Open access
Aug 2026
Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in Italy.
Vaccination of OAs and AIR individuals with one dose of aRSVPreF3 has the potential to reduce RSV disease-associated burden and direct costs for the Italian National Healthcare System over a 5-year period.
A. Puggina, Eleftherios Zarkadoulas, F. Rumi et al.
· The European journal of heal... · 0 citations